This section is intended for UK healthcare professionals. If you are a member of the public click here. If you have been prescribed Ninlaro click here.

Extended Efficacy. Extended Possibilities.

NINLARO + Rd significantly extends PFS vs Rd alone and offers a manageable side effect profile with the convenience of an all‑oral regimen 1,2

NINLARO is the first and only oral PI licensed in combination with Rd for the treatment of adult patients with MM who have received at least 1 prior therapy 2

Oral NINLARO was studied in a broad group of RRMM patients who were treated to progression. 1 TOURMALINE‑MM1 is the first global, phase III, double‑blind, placebo‑controlled study investigating an oral PI in RRMM patients. The trial compared NINLARO + Rd as part of an all‑oral regimen versus placebo + Rd in 722 RRMM patients treated with 1‑3 prior therapies 1

TOURMALINE‑MM1 — the first global, phase III, double‑blind, placebo-controlled study investigating an oral PI in RRMM patients1

TOURMALINE‑MM1 enrolled a broad group of RRMM patients who were treated to progression1

The trial compared NINLARO + Rd as part of an all-oral regimen versus placebo + Rd in 722 RRMM patients treated with 1-3 prior therapies1

TOURMALINE‑MM1 study design1

TOURMALINE-MM1 study design

* Stratification: 1 vs 2 or 3 prior therapies; PI exposed vs PI naive; and International Staging System (ISS) stage I or II vs III1,2

Defined as patients with del(17), t(4;14) or t(14;16)1

Oral NINLARO was studied in a broad group of RRMM patients, including patients with high‑risk cytogenetics and mild-to-moderate renal impairment1,2

Patients enrolled in TOURMALINE‑MM11,2

* Stratification factor 2

A patient who received both a prior PI and a prior IMiD would count for both categories 2

Primary refractory, defined as patients that were refractory to all lines of previous treatment(s) (ie. patients who have never responded to any therapies received), was documented in 7% and 6% of patients in the NINLARO and placebo regimens, respectively. Patients refractory to PIs or lenalidomide were excluded 1,2

§ Defined as patients with del(17), t(4;14) or t(14;16)1

  • Clinical laboratory evaluations for high‑risk cytogenetic markers, including del(17), t(4;14) and t(14;16) were performed by a central laboratory. Positivity for del(17) was defined by a percentage of positive cells that were above the technical background cut-off of 5%